CN117003878B - 抗sFLT-1蛋白的单克隆抗体及应用 - Google Patents
抗sFLT-1蛋白的单克隆抗体及应用 Download PDFInfo
- Publication number
- CN117003878B CN117003878B CN202311271528.8A CN202311271528A CN117003878B CN 117003878 B CN117003878 B CN 117003878B CN 202311271528 A CN202311271528 A CN 202311271528A CN 117003878 B CN117003878 B CN 117003878B
- Authority
- CN
- China
- Prior art keywords
- sflt
- protein
- monoclonal antibody
- clone1
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 208000002296 eclampsia Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 20
- 238000001514 detection method Methods 0.000 abstract description 13
- 201000011461 pre-eclampsia Diseases 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 11
- 238000002156 mixing Methods 0.000 abstract description 10
- 239000006228 supernatant Substances 0.000 abstract description 10
- 238000002965 ELISA Methods 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 238000001261 affinity purification Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000004927 fusion Effects 0.000 abstract description 3
- 210000004408 hybridoma Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004945 emulsification Methods 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- AAYSIOJYGRABGS-UHFFFAOYSA-N 3-[9-[4-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-2,6-dimethylphenoxy]carbonylacridin-10-ium-10-yl]propane-1-sulfonate Chemical compound C=1C(C)=C(OC(=O)C=2C3=CC=CC=C3[N+](CCCS([O-])(=O)=O)=C3C=CC=CC3=2)C(C)=CC=1C(=O)ON1C(=O)CCC1=O AAYSIOJYGRABGS-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000091 Maternal Death Diseases 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- -1 acridine ester Chemical class 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000050995 human FLT1 Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了抗sFLT‑1蛋白的单克隆抗体及应用，单克隆抗体为sFLT‑1‑Clone1，sFLT‑1‑Clone1的重链可变区氨基酸序列如SEQ ID NO.1所示，sFLT‑1‑Clone1的轻链可变区氨基酸序列如SEQ ID NO.2所示。制备方法：将亲和纯化后的sFLT‑1与弗氏佐剂进行等体积混合乳化，采集小鼠血液分离血清，筛选免疫较好的小鼠进行杂交瘤融合实验，以sFLT‑1作为酶标板包被抗原，取上清进行酶联免疫吸附测定，筛选出优质阳性细胞株，并进行两轮的细胞亚克隆。同时也提供了上述抗体的子痫前期诊断检测试剂盒，从而提高诊断试剂的特异性和灵敏度。
Description
技术领域
本发明属于抗体的制备及序列测定领域，具体涉及抗sFLT-1蛋白的单克隆抗体及应用。
背景技术
可溶性FMS样酪氨酸激1(Soluble fms-like tyrosine kinase 1,sFLT-1)是一种抗血管生成蛋白，被认为能调节先兆子痫的体征和症状。sFLT-1也称为可溶性血管内皮生长因子受体，是血管内皮生长因子受体（vascular endothelial growth factorreceptor，VEGFR）1的分泌性剪接变体。sFLT-1能与内皮细胞表面受体VEGFR-1和VEGFR-2结合形成异源二聚体，进而阻断VEGF和胎盘生长因子（placental growth factor，PlGF）的生物学活性，引起血管生成障碍和内皮损伤。近年来，随着研究的不断深入，sFLT-1的不同剪接体形式逐渐被认识。可溶性fms样酪氨酸激酶受体1（Flt-1）基因编码的是含有30个外显子的mRNA，其前体mRNA经剪切形成全长的膜型Flt-1分子及4种可溶性剪接体。
子痫前期是一种妊娠高血压类疾病，全球范围内每年可造成50多万例胎儿和新生儿死亡以及7万多例孕产妇死亡。临床研究表明，sFLT-1浓度在子痫前期发病前约5周便出现升高，早发型、晚发型以及非早产型子痫前期高风险孕妇的sFLT-1在出现症状前均发生动态变化，对子痫前期进行有效的早筛和全方位管理治疗，对保障母婴健康及生命安全具有重要意义。子痫前期常规的检测方法是通过血压、蛋白尿、血清肌酐和血小板浓度等生化指标的变化进行判定。这种传统诊断方式的标准较为宽泛，并且与一些临床症状重叠的疾病不易区分。因此，在临床上亟需开发一种针对子痫前期疾病的特异性诊断方法。sFLT-1可以作为特异性的循环系统标志物对子痫前期的疾病发展进行预测，对子痫前期临床诊断起到辅助作用，进而为孕产妇及新生儿的生命健康安全提供特异性的临床诊断依据。
开发性能优异的sFLT-1免疫诊断试剂的核心原料是抗sFLT-1单克隆抗体，有些厂商的特异性和灵敏度不高，所以开发开发性能优异的sFLT-1诊断试剂非常有必要，同时也期望能够进一步推动诊断试剂的国产化。
发明内容
为解决灵敏性、特异性的问题，本发明提供了抗sFLT-1蛋白的单克隆抗体。该抗体性能优异、准确性高。同时提供了基于上述sFLT-1抗体的化学发光试剂盒，能对子痫前期临床诊断起到辅助作用。
本发明提供如下技术方案：
抗sFLT-1蛋白的单克隆抗体，单克隆抗体为sFLT-1-Clone1，
sFLT-1-Clone1的重链可变区氨基酸序列：
EVQLQQSGAPPVKPGASVKLCCTASGFNIDDTYIHWVKQRPEQGLEWIGRIDPADGDTKYDPKFQGKATITADTSSNTAYLQLSRLTSEDTAVYYCARPSLYDGYYPFAYWGGGTLVTVSA
sFLT-1-Clone1的轻链可变区氨基酸序列：
DVVMTQTPLSLSVSLGDQADISCRSSQSLNYSNRHTYLHWYLQKPGQSPQLLIFLVSNRFSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYFCSQSTHLPTTFGSGTKLEIK
抗sFLT-1蛋白的单克隆抗体的制备方法：
sFLT-1蛋白的表达生产：将pTT5-sFLT-1表达质粒与转染试剂PEI混匀后，转染HEK293细胞，同时在OPM-293 CD03 Medium细胞培养基中加入增强剂和辅料进行培养，当细胞活率<70%后，收集细胞培养物，离心并收集细胞上清。
sFLT-1蛋白的亲和纯化：细胞上清用盐和咪唑充分重悬过滤后，用预装重力柱进行亲和纯化，通过梯度咪唑浓度进行洗杂和洗脱，SDS-PAGE跑胶检测蛋白纯度，将蛋白透析至磷酸盐缓冲液中，0.22μm滤器无菌过滤后，BCA测定蛋白浓度。
将亲和纯化后的sFLT-1蛋白与弗氏佐剂进行等体积混合乳化，免疫计量为100ug/只小鼠，3周后进行加强免疫，免疫计量为50ug/只小鼠，后期间隔2周每次，采集小鼠血液分离血清，酶联免疫吸附测定抗体效价，筛选免疫较好的小鼠进行杂交瘤融合实验，经过HAT筛选培养基筛选培养后，以sFLT-1作为酶标板包被抗原，取上清进行酶联免疫吸附测定，筛选出优质阳性细胞株，并进行两轮的细胞亚克隆，克隆出单克隆细胞株，用无血清培养和发酵细胞株，收集培养上清。
抗sFLT-1蛋白的单克隆抗体在制备子痫早期诊断试剂盒中的应用。
单克隆抗体用于sFLT-1化学发光试剂盒。试剂盒使用sFLT-1-Clone1作为包被抗体。
与现有技术相比，本发明的有益效果是：
本发明提供了抗sFLT-1蛋白，用于制备诊断用单克隆抗体，本发明的抗sFLT-1蛋白的单克隆抗体为sFLT-1-Clone1，能够识别免疫原，此抗体组合具有特异性和高亲和力的特点，同时也提供了基于上述抗体的化学发光检测试剂盒，可以对子痫前期疾病的特异性诊断，从而提高诊断试剂的特异性和灵敏度，对于临床患者子痫的早期诊断、病情评估具有重要意义。
附图说明
图1为本发明检测试剂盒与同类产品相关性对比图。
实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1 sFLT-1蛋白表达载体的构建
在NCBI官网上查找人sFLT-1氨基酸序列，在蛋白氨基酸的C端加上组氨酸标签，利用密码子优化软件在哺乳动物细胞表达系统中优化密码子，基因合成后利用EcoRI/BamHI限制性内切酶酶切位点，将基因克隆至pTT5表达载体中，构建pTT5-sFLT-1表达质粒，并测序验证基因序列。
实施例2 sFLT-1蛋白的表达生产
转染前一天，细胞以0.8×106/ml接种于细胞培养瓶，以OPM-293 CD03 Medium培养液培养，置于37℃，5%CO2培养箱中，至细胞融合度达到80%-90%，活力大于95%时进行转染，pTT5-sFLT-1表达载体与聚醚酰亚胺混匀后，室温孵育15-30min，缓慢加入到HEK293细胞中，加入增强剂和辅料，于 37℃，5%CO2培养箱中继续培养。当细胞活率<70%后，收集细胞培养物，8000 g离心10 min，收集上清液，再通过12000 g，4℃离心30 min，收集细胞上清。
实施例3 sFLT-1蛋白的亲和纯化
细胞上清中加入NaCl和咪唑，并将工作浓度分别调整至300 mM和5 mM后再用0.22滤膜过滤，Ni TED-6FF beads预装重力柱进行亲和纯化，20mM PB，300mM NaCl，10%甘油，50mM咪唑，pH8.0溶液进行洗杂，20mM PB，300mM NaCl，10%甘油，250mM咪唑，pH8.0溶液进行洗脱，SDS-PAGE跑胶检测蛋白纯度，将蛋白透析至20mM PB，300mM NaCl，10%甘油，pH8.0缓冲液中，0.22um滤器无菌过滤后，BCA测定蛋白浓度。
实施例4 单克隆抗体的制备
将sFLT-1蛋白与弗氏佐剂进行等体积混合乳化，免疫计量为100ug/只小鼠，皮下多点注射，3周后进行加强免疫，免疫计量为50ug/只小鼠，后期间隔2周每次，采集小鼠血液分离血清，酶联免疫吸附法测定抗体效价，筛选免疫较好的小鼠进行杂交瘤融合实验，经过10天左右的HAT筛选培养基筛选培养后，以sFLT-1作为酶标板包被抗原，取上清进行酶联免疫吸附法测定，筛选出优质阳性细胞株，并进行两轮的细胞亚克隆，克隆出单克隆细胞株，用无血清培养和发酵细胞株，收集培养上清，进行抗体纯化，将纯化后的抗体进行诊断性能分析。
实施例5 单克隆抗体性能分析
基于双抗体夹心法和吖啶酯发光法原理制备试剂盒。
1、羧基磁珠包被抗体
将购买的的羧基磁珠充分混匀，取出相应量的磁珠置于离心管，使用磁力架去除上清液，清洗后加入包被活化液，混匀后加入包被活化液溶解的EDC，充分混匀后室温颠倒活化0.5-1h；
超声分散磁珠，使用包被活化液清洗三次，加入本发明的包被抗体，充分混匀后室温颠倒反应2-3h；
超声分散磁珠，加入封闭剂，充分混匀后室温颠倒封闭1-2h；
超声分散磁珠，使用磁力架去除上清液，清洗三次，加入磁珠保存液将磁珠稀释至浓度为0.25mg/mL待用。
上述磁珠保存液配方为50mM 三羟甲基氨基甲烷、0.2% Tween-20、0.85% NaCl、2%牛血清白蛋白、0.2% Proclin-300。
2、吖啶酯标记抗体
将NHS酯化的吖啶酯（NSP-DMAE-NHS）与本发明的包被抗体按照分子摩尔比10：1的比例在1×PBS中颠倒混匀标记反应1-2h；
反应结束后将标记液转移至14kD透析袋中，1×PBS中旋转透析，换液6-7次，每次1-2h；
透析过夜后取出标记液，使用分光光度计测试标记液中蛋白含量，计算并添加保护液，充分混匀后可置于-20-22℃保存，上机测试时使用标记保存液将蛋白浓度稀释至0.5ug/mL待用。
上述标记保存液的配方为0.1M MES缓冲液、0.2% Tween-20、0.85% NaCl、2% 牛血清白蛋白、0.2% Proclin-300。
3、配制校准品和质控品
使用抗原稀释液将sFLT-1抗原分别稀释至0、10、50、100、500、1000、5000、10000、50000、100000 pg/mL，分装至校准品管中。
使用抗原稀释液将sFLT-1抗原稀分别释液至80pg/mL、1000 pg/mL，分装至质控品管中。
上述抗原稀释液配方为1×PBS、1% 牛血清白蛋白。
检测试剂盒与同类产品对比：
实施例中的sFLT-1化学发光检测试剂盒与罗氏公司的产品在120例临床标本上进行了相关性对比，数据如图1所示。相关系数R2为0.9823。说明本发明的试剂盒能准确检测sFLT-1含量，为临床诊断提供依据，能够充分满足临床体外诊断检测需求。
检测试剂盒灵敏度和精密度考察：
按照临床和实验室标准协会灵敏度验证分析指南文件CLSI:EP17-A2对本发明中的试剂盒的空白限和检测限进行了研究，结果表明空白限和检测限分别为3 pg/mL和5 pg/mL。
按照临床和实验室标准协会精密度验证分析指南文件CLSI:EP5-A3对本发明的试剂盒进行精密度研究，使用3个批号的试剂和校准品，对2个水平的质控品进行了检测，每天上下午各检测两次，连续考察5天，结果表明各批次室内总精密度小于5%。
检测试剂盒抗干扰能力分析：
在sFLT-1浓度约为80 pg/mL和1000 pg/mL浓度水平的两个血清样本中分别添加不同浓度的干扰物，以未添加组为对照，添加组和对照组两者相对偏差小于5%为干扰可接受标准，研究不同干扰物的最大浓度水平（不超过临床可见最高浓度）。
表1 检测试剂盒抗干扰能力分析数据
结果表明如表1中的浓度时对检测结果干扰不明显。
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (5)
1.抗sFLT-1蛋白的单克隆抗体，其特征在于：单克隆抗体为sFLT-1-Clone1，
所述sFLT-1-Clone1的重链可变区氨基酸序列如SEQ ID NO.1所示，sFLT-1-Clone1的轻链可变区氨基酸序列如SEQ ID NO.2所示。
2.权利要求1所述的抗sFLT-1蛋白的单克隆抗体在制备患者子痫早期诊断试剂中的应用。
3.根据权利要求2所述的抗sFLT-1蛋白的单克隆抗体在制备患者子痫早期诊断试剂中的应用，其特征在于：单克隆抗体用于sFLT-1化学发光试剂盒。
4. sFLT-1化学发光试剂盒，其特征在于：含有权利要求1中的sFLT-1-Clone1。
5.根据权利要求4所述的sFLT-1化学发光试剂盒，其特征在于：试剂盒使用sFLT-1-Clone1作为包被抗体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311271528.8A CN117003878B (zh) | 2023-09-28 | 2023-09-28 | 抗sFLT-1蛋白的单克隆抗体及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311271528.8A CN117003878B (zh) | 2023-09-28 | 2023-09-28 | 抗sFLT-1蛋白的单克隆抗体及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117003878A CN117003878A (zh) | 2023-11-07 |
| CN117003878B true CN117003878B (zh) | 2023-12-05 |
Family
ID=88562128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311271528.8A Active CN117003878B (zh) | 2023-09-28 | 2023-09-28 | 抗sFLT-1蛋白的单克隆抗体及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117003878B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117285635B (zh) * | 2023-11-23 | 2024-01-26 | 南京佰抗生物科技有限公司 | 抗肝素结合蛋白的单克隆抗体组合物及应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914552A1 (en) * | 2006-10-20 | 2008-04-23 | The University Of Newcastle Research Associates Limited | Method for identifying women with an increased risk of pre-eclampsia |
| CN101781370A (zh) * | 2009-05-21 | 2010-07-21 | 浙江大学 | 可溶性血管内皮生长因子受体重组融合蛋白及用途 |
| CN107807241A (zh) * | 2017-11-03 | 2018-03-16 | 太原瑞盛生物科技有限公司 | 一种血管内表皮生长因子受体1的磁微粒化学发光检测试剂盒及制备方法 |
| CN108686727A (zh) * | 2018-06-26 | 2018-10-23 | 宁波奥丞生物科技有限公司 | 快速定量检测PLGF和sFLT-1的微流控芯片 |
| WO2019026870A1 (ja) * | 2017-08-01 | 2019-02-07 | 学校法人学文館 | ｓＦｌｔ－１（可溶型血管内皮増殖因子受容体－１）の新規測定法 |
| CN110488005A (zh) * | 2019-09-26 | 2019-11-22 | 天津华科泰生物技术有限公司 | 一种快速检测孕妇可溶性血管内皮生长因子受体-1的免疫层析检测卡及其制备方法 |
| CN112946299A (zh) * | 2021-01-29 | 2021-06-11 | 暨南大学 | 定量ftl的产品在制备子痫前期诊断工具中的应用 |
| CN113801226A (zh) * | 2021-11-19 | 2021-12-17 | 南京佰抗生物科技有限公司 | 抗人PlGF鼠源单克隆抗体及应用 |
| CN113817064A (zh) * | 2021-11-22 | 2021-12-21 | 南京佰抗生物科技有限公司 | 抗人chi3l1鼠源单克隆抗体及应用 |
-
2023
- 2023-09-28 CN CN202311271528.8A patent/CN117003878B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914552A1 (en) * | 2006-10-20 | 2008-04-23 | The University Of Newcastle Research Associates Limited | Method for identifying women with an increased risk of pre-eclampsia |
| CN101781370A (zh) * | 2009-05-21 | 2010-07-21 | 浙江大学 | 可溶性血管内皮生长因子受体重组融合蛋白及用途 |
| WO2019026870A1 (ja) * | 2017-08-01 | 2019-02-07 | 学校法人学文館 | ｓＦｌｔ－１（可溶型血管内皮増殖因子受容体－１）の新規測定法 |
| CN107807241A (zh) * | 2017-11-03 | 2018-03-16 | 太原瑞盛生物科技有限公司 | 一种血管内表皮生长因子受体1的磁微粒化学发光检测试剂盒及制备方法 |
| CN108686727A (zh) * | 2018-06-26 | 2018-10-23 | 宁波奥丞生物科技有限公司 | 快速定量检测PLGF和sFLT-1的微流控芯片 |
| CN110488005A (zh) * | 2019-09-26 | 2019-11-22 | 天津华科泰生物技术有限公司 | 一种快速检测孕妇可溶性血管内皮生长因子受体-1的免疫层析检测卡及其制备方法 |
| CN112946299A (zh) * | 2021-01-29 | 2021-06-11 | 暨南大学 | 定量ftl的产品在制备子痫前期诊断工具中的应用 |
| CN113801226A (zh) * | 2021-11-19 | 2021-12-17 | 南京佰抗生物科技有限公司 | 抗人PlGF鼠源单克隆抗体及应用 |
| CN113817064A (zh) * | 2021-11-22 | 2021-12-21 | 南京佰抗生物科技有限公司 | 抗人chi3l1鼠源单克隆抗体及应用 |
Non-Patent Citations (2)
| Title |
|---|
| Assessing the Circulating Placental-Specific Anti-angiogenic Protein sFLT-1 e15a in Preeclampsia;Kirsten Palmer;《Preeclampsia》;第2605卷(第6期);第27-37 * |
| 可溶性fms样酪氨酸激酶1时间分辨荧光免疫分析法的建立;吴鸿峰等;《现代免疫学》;第42卷(第5期);第375-380页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117003878A (zh) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5807300B2 (ja) | 試料中のｃ反応性蛋白質の測定方法及び測定試薬 | |
| CN117003878B (zh) | 抗sFLT-1蛋白的单克隆抗体及应用 | |
| CN109975536B (zh) | 抗缪勒激素胶乳增强比浊法检测试剂盒及其制备使用方法 | |
| CN109580959B (zh) | 一种检测肝素结合性表皮生长因子的elisa试剂盒 | |
| JP5554247B2 (ja) | ヒト体液中のシスタチンｃ測定方法 | |
| CN116874597B (zh) | 鼠抗人血管内皮生长因子的单克隆抗体及应用 | |
| CN114478785A (zh) | 抗人chi3l1鼠源单克隆抗体及应用 | |
| JP2020507775A (ja) | 喘息またはアレルギー疾患迅速診断用キット | |
| CN116874596B (zh) | 抗S100β蛋白的单克隆抗体及其制备方法和应用 | |
| CN116536269B (zh) | 一种cho细胞株、纤维蛋白原降解产物fdp抗体及其应用 | |
| JP2000512123A (ja) | ネフロパシー―関連免疫グロブリンｇ及びそのための抗体 | |
| CN107746430B (zh) | 一种gp73 c端抗原的制备及其应用 | |
| CN117285635B (zh) | 抗肝素结合蛋白的单克隆抗体组合物及应用 | |
| CN112710835B (zh) | 一种生殖系统疾病检测试剂盒 | |
| CN117003869B (zh) | 抗il-10蛋白的单克隆抗体组合物及应用 | |
| CN117285625B (zh) | 抗泌乳素蛋白的单克隆抗体及应用 | |
| CN117143242B (zh) | 抗Galectin-3蛋白的单克隆抗体组合物及应用 | |
| CN105987998B (zh) | 人组织激肽释放酶1elisa定量检测试剂盒 | |
| CN105988004B (zh) | 人组织激肽释放酶1胶体金定量检测试纸卡 | |
| CN116773813B (zh) | 一种vegfr1检测试剂盒的制备及应用 | |
| CN110618277B (zh) | 乳胶增强免疫比浊法测定粪胰弹性蛋白酶-1 | |
| CN112694533B (zh) | 生殖系统疾病检测试剂盒 | |
| CN113621059B (zh) | 一种β2-微球蛋白检测试剂盒及其临床应用 | |
| CN117430701A (zh) | 抗人钙卫蛋白的单克隆抗体组合物及应用 | |
| CN115060907A (zh) | 一种Nogo-B蛋白表达量检测ELISA试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |